FGF23 and chronic kidney disease: Experimental evidence suggests that DMP1 supplementation in CKD models improves bone quality, suppresses fibroblast growth factor 23 (FGF23) overproduction, and attenuates associated cardiovascular complications (Zhang and Chen, 2023).